Department of Gynecology and Obstetrics, LinYi People's Hospital, Linyi, Shandong, China (mainland).
Department of Pathology and Pathophysiology, LinYi People's Hospital, Linyi, Shandong, China (mainland).
Med Sci Monit. 2018 May 10;24:3050-3055. doi: 10.12659/MSM.906647.
BACKGROUND Advanced-stage serous ovarian carcinoma results in the majority of deaths from ovarian carcinoma. The histone chaperone, Holliday junction-recognizing protein (HJURP), binds with centromere protein-A (CENP-A) and its expression has been shown to be a prognostic biomarker in some cancers. The aim of this study was to investigate the role of HJURP expression in advanced-stage serous ovarian carcinoma. MATERIAL AND METHODS Ninety-eight patients with advanced-stage serous ovarian carcinoma, who had tumor tissue samples available, were studied. Expression levels of HJURP were detected using immunohistochemistry (IHC) and were correlated with HJURP expression and patient clinicopathological factors. Fisher's correlation coefficient, Kaplan-Meier survival curves, the log-rank test, and Cox's regression proportional hazards model were performed to analyze the significance of factors affecting survival rate and independent prognostic factors. RESULTS Increased expression levels of HJURP in advanced-stage serous ovarian carcinoma were found in 33.67% (33/98) of cases; low expression levels of HJURP were found in 66.33% (65/98) of cases. High expression levels of HJURP were significantly associated with lymph node metastases (P=0.018), and lower overall survival (P=0.002). HJURP expression was identified as an independent prognostic biomarker for patients with advanced serous ovarian cancer in this study group of 98 patients (P=0.013). CONCLUSIONS Increased expression of HJURP was identified as an independent negative prognostic biomarker for patients with advanced serous ovarian cancer in this study. Further studies are required to determine whether HJURP expression in serous ovarian carcinoma may have a role in guiding clinical management by stratifying patients according to risk.
晚期浆液性卵巢癌是导致卵巢癌死亡的主要原因。组蛋白伴侣 Holliday 连接识别蛋白（HJURP）与着丝粒蛋白 A（CENP-A）结合，其表达已被证明是某些癌症的预后生物标志物。本研究旨在探讨 HJURP 表达在晚期浆液性卵巢癌中的作用。
研究了 98 例有肿瘤组织样本的晚期浆液性卵巢癌患者。使用免疫组织化学（IHC）检测 HJURP 的表达水平，并将其与 HJURP 表达和患者临床病理因素相关联。Fisher 相关系数、Kaplan-Meier 生存曲线、对数秩检验和 Cox 回归比例风险模型用于分析影响生存率的因素的显著性和独立预后因素。
在 33.67%（33/98）的病例中发现晚期浆液性卵巢癌中 HJURP 表达水平升高；在 66.33%（65/98）的病例中发现 HJURP 表达水平降低。高水平的 HJURP 表达与淋巴结转移显著相关（P=0.018），总生存率降低（P=0.002）。在本研究的 98 例患者中，HJURP 表达被确定为晚期浆液性卵巢癌的独立预后生物标志物（P=0.013）。
在本研究中，HJURP 的高表达被确定为晚期浆液性卵巢癌患者的独立负预后生物标志物。需要进一步研究以确定浆液性卵巢癌中 HJURP 的表达是否可以通过根据风险分层来指导患者的临床管理。
